The impact of new trends in POCTs for companion diagnostics, non-invasive testing and molecular diagnostics

Point-of-care diagnostics have been slowly developing over several decades and have taken on a new importance in current healthcare delivery for both diagnostics and development of new drugs. Molecular diagnostics have become a key driver of technology change and opened up new areas in companion diagnostics for use alongside pharmaceuticals and in new clinical approaches such as non-invasive testing. Future areas involving smartphone and other information technology advances, together with new developments in molecular biology, microfluidics and surface chemistry are adding to advances in the market. The focus for point-of-care tests with molecular diagnostic technologies is focused on advancing effective applications.

[1]  A. Nardone,et al.  P2.163 Do “In-Clinic” Molecular and Non-Molecular Rapid Tests Improve Patient Management? , 2013, Sexually Transmitted Infections.

[2]  Nick Crabb,et al.  The Health Technology Assessment of Companion Diagnostics: Experience of NICE , 2014, Clinical Cancer Research.

[3]  Formulary staff,et al.  FDA issues final guidance on mobile medical apps , 2013 .

[4]  P. Lorgelly,et al.  Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist , 2015, Expert review of molecular diagnostics.

[5]  G. Rasi,et al.  Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union , 2014, Clinical Cancer Research.

[6]  Matthew J. Thompson,et al.  Current and future use of point-of-care tests in primary care: an international survey in Australia, Belgium, The Netherlands, the UK and the USA , 2014, BMJ Open.

[7]  Yu-Tseung Liu.  A technological update of molecular diagnostics for infectious diseases. , 2008, Infectious disorders drug targets.

[8]  D. Wertz.  Ethical, social and legal issues in pharmacogenomics , 2003, The Pharmacogenomics Journal.

[9]  Li Jiang,et al.  Solar thermal polymerase chain reaction for smartphone-assisted molecular diagnostics , 2014, Scientific Reports.

[10]  Nello Blaser,et al.  Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study , 2013, AIDS.

[11]  Alan Brown,et al.  User Perspectives of Cardiac Marker Point-of-Care Testing for Hospital-Based Chest Pain Diagnosis , 2008 .

[12]  Charlotte A Gaydos,et al.  Use of tablet-based kiosks in the emergency department to guide patient HIV self-testing with a point-of-care oral fluid test , 2013, International journal of STD & AIDS.

[13]  Lesley E Scott,et al.  Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions , 2014, BMC Medicine.

[14]  Y. Ho,et al.  DNA-based nanosensors for next-generation clinical diagnostics via detection of enzyme activity , 2014, Expert review of molecular diagnostics.

[15]  Michael R. Speicher,et al.  A survey of tools for variant analysis of next-generation genome sequencing data , 2013, Briefings Bioinform..

[16]  Larry J Kricka,et al.  Prospects for the commercialization of chemiluminescence-based point-of-care and on-site testing devices , 2014, Analytical and Bioanalytical Chemistry.

[17]  David Huckle,et al.  Point-of-care diagnostics: an advancing sector with nontechnical issues , 2008, Expert review of molecular diagnostics.

[18]  Andrew St John,et al.  Economic Evidence and Point-of-Care Testing. , 2013, The Clinical biochemist. Reviews.

[19]  H. Kong,et al.  Multiple strategies to improve sensitivity, speed and robustness of isothermal nucleic acid amplification for rapid pathogen detection , 2011, BMC biotechnology.

[20]  F. López-Ríos,et al.  A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests , 2014, Expert review of molecular diagnostics.

[21]  D. Huckle,et al.  Point-of-care diagnostics - is this driven by supply or demand? , 2010, Expert opinion on medical diagnostics.

[22]  M F Burritt,et al.  Point-of-care testing. , 1995, Mayo Clinic proceedings.

[23]  M. Cho,et al.  Commercial landscape of noninvasive prenatal testing in the United States , 2013, Prenatal diagnosis.

[24]  Mauro Ferrari,et al.  Point-of-care technologies for molecular diagnostics using a drop of blood. , 2014, Trends in biotechnology.

[25]  M. Klepser,et al.  Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy. , 2014, Journal of the American Pharmacists Association : JAPhA.

[26]  J. Kaldor,et al.  A Laboratory-Based Evaluation of Four Rapid Point-of-Care Tests for Syphilis , 2014, PloS one.

[27]  Rosanna W. Peeling,et al.  Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control , 2013, Current opinion in infectious diseases.

[28]  C. Moore.  Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line? , 2013, The Journal of hospital infection.

[29]  H. Barros,et al.  European perinatal health report by the Euro-Peristat project : [better statistics for better health for pregnant women and their babies] , 2008 .

[30]  Lesley Scott,et al.  A laboratorian's experience of implementing multiple point-of-care testing in HIV antiretroviral treatment clinics in South Africa. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[31]  R. Oriol,et al.  Lewis Histo‐Blood Group System and Associated Secretory Phenotypes , 1995, Vox sanguinis.

[32]  S. Zielinski,et al.  International Court of Justice , 2002, International Organization.

[33]  Jeffrey Morse.  Advanced Nanomanufacturing for Wearable Human Performance Monitoring Sensor Platforms , 2014 .

[34]  C. Murgatroyd.  Epigenetic programming of neuroendocrine systems during early life , 2014, Experimental physiology.

[35]  Morten Ruhwald,et al.  Point‐of‐care diagnosis of tuberculosis: Past, present and future , 2013, Respirology.

[36]  J. Khoury,et al.  Next-generation companion diagnostics: promises, challenges, and solutions. , 2015, Archives of pathology & laboratory medicine.

[37]  Niko Hildebrandt,et al.  Toward sensitive, quantitative point-of-care testing (POCT) of protein markers: miniaturization of a homogeneous time-resolved fluoroimmunoassay for prostate-specific antigen detection. , 2011, The Analyst.

[38]  A. Thomas.  Point of Care Testing – Needs, Opportunity and Innovation , 2011 .

[39]  M. Rochon.  DNA Sequencing Versus Standard Prenatal Aneuploidy Screening , 2014 .

[40]  C. Alves.  Select point-of-care testing of patients admitted for chest pain in an emergency department of a secondary hospital: does it decrease the length of stay? , 2014 .

[41]  Guido Freckmann,et al.  Considerations for an Institution for Evaluation of Diabetes Technology Devices to Improve Their Quality in the European Union , 2013, Journal of diabetes science and technology.

[42]  Effy Vayena,et al.  The challenge of personal genomics in Germany , 2013, Nature Biotechnology.

[43]  R. Rava,et al.  DNA sequencing versus standard prenatal aneuploidy screening. , 2014, The New England journal of medicine.

[44]  Chris Sheehan,et al.  Introduction to Immunoassay Product Technology in Clinical Diagnostic Testing , 2013 .

[45]  S. Scott,et al.  Clinical Pharmacogenomics: Opportunities and Challenges at Point of Care , 2013, Clinical pharmacology and therapeutics.

[46]  C. Rozand.  Paper-based analytical devices for point-of-care infectious disease testing , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[47]  A. Brown,et al.  Assessment of User Perspectives of Cardiac Point of Care Technologies in Chest Pain Diagnosis , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[48]  Jiming Bao,et al.  Transmissive Nanohole Arrays for Massively-Parallel Optical Biosensing , 2014, ACS photonics.

[49]  K. Sin,et al.  Evidence-based point-of-care diagnostics: current status and emerging technologies. , 2013, Annual review of analytical chemistry.

[50]  Marc Madou,et al.  Present technology and future trends in point-of-care microfluidic diagnostics. , 2013, Methods in molecular biology.

[51]  Yasuyoshi Mori,et al.  Novel Molecular Diagnostic Platform for Tropical Infectious Diseases , 2012 .

[52]  Korbinian Schneeberger,et al.  Using next-generation sequencing to isolate mutant genes from forward genetic screens , 2014, Nature Reviews Genetics.

[53]  A. Bhalla.  Bedside point of care toxicology screens in the ED: Utility and pitfalls , 2014, International journal of critical illness and injury science.

[54]  Christopher G Chute,et al.  Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.

[55]  Andrew St John,et al.  Existing and Emerging Technologies for Point-of-Care Testing. , 2014, The Clinical biochemist. Reviews.

[56]  M. Rishniw,et al.  Survey of point-of-care instrumentation, analysis, and quality assurance in veterinary practice. , 2014, Veterinary clinical pathology.